First evaluation of microvascular damage through nailfold capillaroscopy of an uncommon case of Raynaud's phenomenon in multiple sclerosis: Case report and literature review
Restricted accessCase reportFirst published online August, 2025
First evaluation of microvascular damage through nailfold capillaroscopy of an uncommon case of Raynaud's phenomenon in multiple sclerosis: Case report and literature review
The occurrence of Raynaud's phenomenon in patients with multiple sclerosis (MS) is infrequently documented in the literature. Some cases have been attributed to interferon-β therapy, while others have emerged in MS patients who sub-sequently developed Raynaud's phenomenon and/or systemic sclerosis. The association between microangiopathic damage and both Raynaud's phenomenon and systemic sclerosis is well-established, leading to the adoption of nailfold video-capillaroscopy (NVC) as a non invasive diagnostic tool for the initial clinical assessment of these conditions.
Case Presentation:
We present a case study of a 42-year-old female patient with Raynaud's phenomenon in MS. The patient underwent NVC in 2023 showing microvascular impairment and after one year and Natalizumab treatment she repeated NVC evaluation with significant improvement in previous microangiopathic changes. A comprehensive literature review regarding the relationship between MS and Raynaud's phenomenon was conducted using electronic databases (PUBMED, UpToDate, Google Scholar, ResearchGate), along with manual searches for relevant articles published up to December 2024.
Discussion:
This case highlights the potential utility of NVC in the ongoing evaluation of microangiopathic damage in MS patients exhibiting Raynaud's phenomenon. By elucidating the overlap between these conditions, NVC may serve as a valuable tool in the clinical management of affected individuals.
HügleTGratzlSDaikelerT, et al.Sclerosing skin disorders in association with multiple sclerosis. Coincidence, underlying autoimmune pathology or interferon induced?Ann Rheum Dis2009; 68: 47–50.
3.
RotULedinekAH. Interferons beta have vasoconstrictive and procoagulant effects: a woman who developed livedo reticularis and Raynaud phenomenon in association with interferon beta treatment for multiple sclerosis. Clin Neurol Neurosurg2013; 115: S79–S81.
4.
LindenD. Severe Raynaud's phenomenon associated with interferon-beta treatment for multiple sclerosis. Lancet1998; 352: 878–879.
5.
AiroPScarsiMRossiM, et al.Onset and enhancement of systemic sclerosis after treatments for multiple sclerosis. Rheumatol Int2008; 28: 703–707.
6.
PelidouSHTsifetakiNGiannopoulosS, et al.Multiple sclerosis associated with systemic sclerosis. Rheumatol Int2007; 27: 771–773.
7.
Etehad TavakolMFatemiAKarbalaieA, et al.Nailfold capillaroscopy in rheumatic diseases: which parameters should be evaluated?Biomed Res Int2015; 2015: 974530.
8.
JungF. From hemorheology to microcirculation and regenerative medicine: fahraeus lecture 2009. Clin Hemorheol Microcirc2010; 45: 79–99.
9.
Dörffler-MellyJLüscherTFWenkM, et al.Endothelin-1 and cold provocation in health, primary Raynaud's phenomenon, and progressive systemic sclerosis. Microvasc Res1996 Sep; 52: 193–197.
10.
FagrellB. Vital microscopy and the pathophysiology of deep venous insufficiency. Int Angiol1995 Sep; 14: 18–22.
11.
KoscielnyJKLatzaRMürsdorfS, et al.Capillary microscopic and rheological dimensions for the diagnosis of von Willebrand disease in comparison to other haemorrhagic diatheses. Thromb Haemost2000 Dec; 84: 981–988.
12.
AdelHEldeebAAHamdyF. Nailfold capillaroscopic changes in patients with glomerular diseases. Reumatol Clin (Engl Ed)2025 Jan; 21: 101803.
13.
Mercadé-TorrasJMGuillén-Del-CastilloABujánS,et al.Nailfold videocapillaroscopy abnormalities and vascular manifestations in Behçet's syndrome. Clin Exp Rheumatol2024 Oct; 42: 2065–2070.
14.
SmithVBeeckmanSHerrickAL, et al.An EULAR study group pilot study on reliability of simple capillaroscopic definitions to describe capillary morphology in rheumatic diseases. Rheumatology (Oxford)2016; 55: 883–890.
15.
JacobJRWeismanMHRosenblattSI, et al.Chronic pernio. A historical perspective of cold-induced vascular disease. Arch Intern Med1986; 146: 1589–1592.
16.
KhoyKMariotteDDeferG, et al.Natalizumab in multiple sclerosis treatment: from biological effects to immune monitoring. Front Immunol2020; 11: 549842.
17.
RudickRAStuartWHCalabresiPA, et al.Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med2006; 354: 911–923.
18.
RuaroBSulliASmithV, et al.Advances in nailfold capillaroscopic analysis in systemic sclerosis. J Scleroderma Relat Disord2018; 3: 122–131.
19.
TrojanoMPellegriniFPaolicelliD, et al.Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. Ann Neurol2009; 66: 513–520.
20.
SpelmanTKalincikTJokubaitisV, et al.Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS. Neurol Clin Pract2016; 6: 102–115.
21.
KalincikTBrownJWLRobertsonN, et al.Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurol2017; 16: 271–281.
22.
LanzilloRQuarantelliMBonavitaS, et al.Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study. Acta Neurol Scand2012; 126: 306–314.
23.
NgHSZhuFZhaoY, et al.Adverse events associated with disease-modifying drugs for multiple sclerosis: a multiregional population-based study. Neurology2024; 102: e208006.
24.
SulliARuaroBCutoloM. Evaluation of blood perfusion by laser speckle contrast analysis in different areas of hands and face in patients with systemic sclerosis. Ann Rheum Dis2014; 73: 2059–2061.
25.
JaegerVKTiklyMXuD, et al.Racial differences in systemic sclerosis disease presentation: a European Scleroderma trials and research group study. Rheumatology (Oxford)2020; 59: 1684–1694.
CruzBAQueirozEDNunesSV, et al.Fênomeno de Raynaud grave associado a terapia com interferon-beta para esclerose múltipla: relato de caso [Severe Raynaud's phenomenon associated with interferon-beta therapy for multiple sclerosis: case report]. Arq Neuropsiquiatr2000; 58: 556–559.
28.
YükselSYükselEPMeriçM. Abnormal nailfold videocapillaroscopic findings in heart failure patients with preserved ejection fraction. Clin Hemorheol Microcirc2020; 77: 115–121.
29.
MartiniR. The compelling arguments for the need of microvascular investigation in COVID-19 critical patients. Clin Hemorheol Microcirc2020; 75: 27–34.
30.
MondiniLConfalonieriPPozzanR, et al.Microvascular alteration in COVID-19 documented by nailfold capillaroscopy. Diagnostics (Basel)2023; 13: 1905.
31.
RuaroBPozzanRConfalonieriP, et al.Gastroesophageal reflux disease in idiopathic pulmonary fibrosis: viewer or actor? To treat or not to treat?Pharmaceuticals (Basel)2022; 15: 1033.
32.
MansuetoNRotondoCCorradoA, et al.Nailfold capillaroscopy : a comprehensive review on common findings and clinical usefulness in non-rheumatic disease. J Med Invest2021; 68: 6–14.
33.
SmithVPizzorniCRiccieriV, et al.Stabilization of microcirculation in patients with early systemic sclerosis with diffuse skin involvement following rituximab treatment: an open-label study. J Rheumatol2016; 43: 995–996.
34.
HughesMBruniCCuomoG, et al.The role of ultrasound in systemic sclerosis: on the cutting edge to foster clinical and research advancement. J Scleroderma Relat Disord2021; 6: 123–132.
35.
Yılmaz TuğanBBünülSDKaraB, et al.Retinal and choroidal vascularity evaluation in pediatric radiologically isolated syndrome and multiple sclerosis. Pediatr Neurol2024 Apr; 153: 34–43.
36.
YilmazHErsoyAIcelE. Assessments of vessel density and foveal avascular zone metrics in multiple sclerosis: an optical coherence tomography angiography study. Eye (Lond)2020 Apr; 34: 771–778.
